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Abstract
Wilms tumor (WT) has been a model to study kidney embryogenesis and tumorigenesis and, although associated with
hereditary, cancer predisposition syndromes, the majority of tumors occur sporadically. To analyze genetic changes in WT
we have defined copy number changes and loss of heterozygosity in 56 Wilms tumors using high resolution oligonucleotide
arrays at a average resolution of ,12 Kb. Consistent deletions were seen on chromosomes 1p, 4q, 7p, 9q, 11p, 11q, 14q,
16q, and 21q. High frequency gains were seen for 1q and lower frequency gains were seen on 7q and chromosomes 8, 12
and 18. The high resolution provided by the SNP mapping arrays has defined minimal regions of deletion for many of these
LOH events. Analysis of CNAs by tumor stage show relatively stable karyotypes in stage 1 tumors and more complex aCGH
profiles in tumors from stages 3–5.
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Introduction
Wilms tumor (WT) is the most common kidney cancer in
children with an incidence of ,1:10,000/year [1]. The tumor
contains blastemic, epithelial and stromal components in its
tradition triphasic histology. Some tumors also show evidence of
further differentiation, providing evidence that WT arises from
embryonic precursor cells that have retained a multilineage
potential [2]. Although WT is largely a sporadic tumor, rare
cases of familial tumors have been described [3–5] and WT is also
associated with various congential syndromes [6] that predispose
to WT, such as the Wilms/Aniridia/GU abnormalities/mental
Retardation (WAGR) syndrome [7], Denys-Drash syndrome [8–
9], Perlman’s syndrome [10] and Beckwith-Weidemann syndrome
[11–12]. In addition, ,10% of WT patients present with early-
onset, bilateral tumors [13], which are considered a hallmark of
hereditary tumors fulfilling the Knudson two-hit hypothesis [14–
15].
The WAGR syndrome was shown to be associated with a
deletion involving 11p13 [7], which led to the eventual cloning of
the WT1 gene [16], a zinc finger gene that has been shown to be
fundamentally important in kidney development [17] and ,50%
of WAGR patients will develop WT [18]. Loss of heterozygosity
(LOH) is considered a manifestation of the Knudson two-hit
hypothesis, which explains the exposure of recessive mutations in
tumor cells through a variety of mechanisms [19]. In sporadic
WT, LOH was also identified at 11p13 [20–21], which supported
the role of WT1 in these tumors as well. In many cases, however,
LOH at 11p13 was accompanied by LOH at 11p15 in sporadic
tumors. Interestingly, duplication of the 11p15 region have been
identified in BWS patients [22–23]. These patients show a 7–10%
risk of developing intra-abdominal tumors [24] including WT and
some of these patients show loss of imprinting of the maternal
11p15 region which was associated with overexpression of the
IGF2 gene [25]. DDS, which shows high incidence of WT
development, was shown to be associated with constitutional WT1
mutations [26].
Although these rare hereditary/syndromic patients implicate
11p13 in Wilms tumorigenesis, only ,10% of sporadic WT show
mutations in WT1 [27]. This observation prompted surveys of
other genetic abnormalities that were present in sporadic tumors.
Early chromosome-based analyses identified common abnormal-
ities involving gain of chromosome 1q and loss of 16q [28–30].
More extensive genome analysis of WT using individual
polymorphic markers [31] defined consistent regions of LOH in
addition to those seen on 11p, involving chromosomes such as 7p
and 16q. With the advent of array-based comparative genomic
hybridization (aCGH), it is now possible to perform whole genome
analyses to identify losses, gains and amplifications across the
genome at high resolution [32–33]. To date, studies of WT have
been undertaken using arrays of BAC clones with resolutions of
,1 Mbp [34] and the Affymetrix 10K SNP mapping array [35].
While these studies have been informative in identifying copy
number abnormalities (CNAs), the resolution is still relatively low
compared with oligonucleotide arrays currently available. In
addition, BAC arrays and most CGH oligonucleotide arrays
cannot define LOH that occurs on a background of copy number
neutral (CNN) karyotypes [36]. The availability of CGH arrays
that carry oligonucleotides defining single nucleotide polymor-
phisms, however, not only allows detection of CNAs but also
LOH, even in the absence of a normal control DNA from the
same individual [36–37]. By combining these two analyses, a more
comprehensive view of the genetic events that have occurred in
specific tumors can be defined, since LOH on a CNN background,
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loss of chromosome regions [36]. We have now performed high-
resolution analysis in 56 WT samples using arrays that provide an
average ,12 Kb resolution to generate a comprehensive survey of
the CGH/LOH events in these tumors. As a result of this analysis,
we have been able to accurately define relatively small regions
within individual chromosome arms that show consistent loss of
heterozygosity.
Results
In this study, 56 Wilms tumors were analyzed for copy number
abnormalities and loss of heterozygosity using the 250 K Sty1
Affymetrix mapping arrays providing an average resolution of
,12 Kb. We have previously demonstrated [38] that higher
resolution arrays did not provide any significant advantage in
CNA detection compared with the 250 K arrays which provide
the most cost effective means of analysis [36,38]. Eight of the
tumors did not show any copy number or LOH abnormalities
(Supplemental Table S1). Although surprising, this is consistent
with previous studies using chromosome-based analyses which
similarly defined normal karyotypes in WT [30]. An additional
five tumors showed no evidence of CNAs but did show regions of
LOH on a CNN background (figure 1). This observation
highlights the advantages of using an array platform that can
simultaneously identify both CNAs and LOH. The remaining 43
tumors showed structural chromosome abnormalities and/or
whole chromosome losses (WCL) and gains (Supplemental Table
S1). Tumor DNA was isolated from snap frozen tissue and so the
aCGH profiles reflect the total heterogeneity in the original
sample.
In this report we first analysed CNAs according to tumor stage,
since it has been suggested that higher stage tumors show more
extensive genetic instability [39]. The clinical staging system used
at the time of diagnosis of the tumors in this study were; Stage I-
tumor limited to the kidney and completely excised; Stage II –
tumor extends beyond the kidney but is completely excised; Stage
III – residual nonhematogenous tumor confined to the abdomen;
Stage IV – Hematogenous metastasis; Stage V – bilateral renal
involvement.
aCGH analysis of Stage I/II tumors
Observations within this series of Wilms tumors are consistent
with the suggestion that low grade tumors are genetically more
stable than higher-grade tumors and reveal fewer CNAs [39]. Of
the 12 stage 1 tumors, 5 showed no CNAs and three others
showed ,3 abnormalities (Supplemental Table S1). GOS 249
showed only CNN LOH for 19q, GOS 207 showed CNN LOH
for 6p and loss of whole chromosome 19 and GOS 130 showed
CNAloss for the distal part of 4p. Thus, minimal CNA/LOH
abnormalities were seen in 8/12 cases (75%). The other 4 tumors
showed more extensive CNAs, mostly involving whole chromo-
some changes (e.g. GOS 101 and GOS 548). In this overall group,
since there were relatively few CNAs, no consistent changes were
observed, although 1q gain was seen in 2/12 and loss of 1p was
seen in only one other cases without 1q gain. Interestingly, in GOS
548, LOH was seen along the length of chromosome 1, but the
CNAloss was only identified for distal 1q. The deletion event,
therefore, most likely occurred after the duplication of the retained
chromosome. Only one tumor (GOS 219) showed CNAloss
involving chromosome 11, which, in this case, did not involve
the WT1 locus. In this tumor, as described for chromosome 1
above, however, LOH was seen along the length of chromosome
11 but CNAloss only involved distal 11q. One tumor showed whole
chromosome 11 loss (GOS 55), accompanied by LOH. 4/12 of
these Stage 1 tumors showed CNN LOH. Only one tumor (GOS
548) showed a relatively unstable karyotype with 1p loss and
multiple whole chromosome losses. Overall this series of tumors
showed relatively stable karyotypes.
There was only one example (GOS 100) of a stage II tumor in
this series which showed relative instability compared with the
majority of stage I tumors. Within this karyotypes, a gain of 1q was
observed together with LOH for 6q. A complex series of events
involving chromosome 11 resulted in CNAloss and LOH for much
of the long arm (figure 2). CNN LOH was present for 11p,
including the WT1 locus, in addition to the CNAloss for two
distinct regions of 11q. Interestingly, the LOH on 11p was
associated with a CNAgain. This tumor showed the 16q loss which
has been associated with poor outcome (see below), although not
accompanied by LOH.
aCGH analysis of Stage III tumors
Stage III tumors are defined as extending out of the kidney into
the abdomen but without hematogenous involvement. Clinically
this represents a more aggressive phenotype which, in this series of
16 tumors, is reflected in generally more unstable karyotypes.
Despite this trend, four tumors showed minimal changes; GOS 92
showed a normal karyotype, GOS 48 showed loss of a whole copy
of chromosome 7, and GOS 16 and GOS 54 showed CNN LOH
for 6p (figure 1) and 16p, respectively as the only detectable
abnormalities. Loss of 16q was seen in five stage III tumors, in one
case as CNN LOH (GOS 54), and another (GOS 404) as WCL
with LOH. Two tumors (GOS 52, GOS 97) showed an almost
identical loss of Chr16;31624102-qter but without LOH, while
another tumor (GOS 11) apparently involved loss of a more distal
region of 16q. In fact, both of these breakpoints are located within
the centromeric regions of this chromosome leading to loss of the
long arm. CNAloss involving 11p was also seen more frequently (5/
16) in stage III tumors than in stage I/II tumors. Of the five
tumors which showed CNN LOH, three involved the whole
chromosome; one (GOS 97) showed CNN LOH and, of the other
two showing CNAloss, one (GOS 206) showed LOH while the
other did not. One tumor, GOS 206, showed exclusive loss of only
the distal Chr11:pter-17449758 region, which did not include the
WT1 locus. In GOS 11, LOH did not extend to the pter region,
but still involved the IGF2 and H19 genes. Two of these stage III
tumors (GOS 128, GOS 370) showed CNAloss involving 11q
(figure 2), where the minimum region of overlap spanned
Chr11;102077451–125002355, which has also been described as
a rare event in previous studies as well [40]. Gain of 1q was also
notably more frequent (7/14) in stage III tumors, only two of
which (GOS 11, GOS 408) were accompanied by loss of 1p.
Of the other notable chromosome events (occurring .2 times)
in this series of stage III tumors were losses involving chromosomes
4 and 22 in three cases and chromosome 21 in five cases
(Supplemental Table S1). The minimal region of loss on Chr:21
was defined by the CNN LOH event in GOS 11. Also notable was
the micro deletion on chromosome 19 in GOS 21 (see below).
aCGH analysis of Stage IV tumors
Of the 10 stage IV tumors in this series, the frequency of CNAs
was generally similar to that seen in the Stage III tumors. One of the
tumors in this group, (GOS 231), showed a normal karyotype. Loss
of chromosome 11 was seen in 5/10 cases, of which all were
associated with LOH. Three of the five involved CNN LOH. These
tumors (e.g. GOS 91, 178, 526) tended to have more stable
karyotypes compared with the others. In GOS 526, 11p loss
involved only 11p13 and not the 11p15 region. Gain of 1q was seen
CGH of Wilms Tumor
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of 7p was seen in 3/10 cases, one including the whole chromosome.
aCGH analysis of Stage V tumors
Six tumors in this series (,10%) were from patients with
bilateral disease, although only one of the two tumors from each
patient was available for analysis. These stage V tumors showed a
similar level of instability as stage IV tumors. Of the six tumors in
this group, 4 (75%) showed LOH for 11p13, and three were
associated with CNN LOH (GOS 541, GOS 566, GOS 586). In
three of these cases (GOS 41, GOS 540 and GOS 586), the 11p
LOH event was the only abnormality in the aCGH karyotypes. 1q
loss was observed in only 1/6 tumors (GOS 12), with
accompanying CNAloss and LOH of 1p.
Overall analysis of CNAs in Wilms tumors
To define consistent CNAs in WT, independent of tumor stage,
we combined the data from all 56 tumors to establish relative
frequencies of specific CNA/LOH events, and also to define
minimal regions of loss and gain associated with these CNAs.
Segmental chromosome losses were infrequent on many (Supple-
mental Table S1) and only chromosomes 1, 4, 11, 14, 16 and 17
showed abnormalities in .4 tumors. In addition, whole chromo-
some losses were observed .3 times only for chromosomes 4, 6,
11, 14 and 21. A summary of the CNA/LOH events on a genome-
wide, low-resolution plot is shown in Figure 3. Loss of
heterozygosity, coincident with CNAloss was seen on average in
only ,60% (37/61) of cases. As we have described previously [38],
this observation likely reflects either heterogeneity in the tumor or
higher ploidy levels in the cells where loss of chromosomal
material on a diploid background results in LOH, whereas a single
chromosome loss on a tetraploid background does not. The
frequency with which whole chromosome losses also resulted in
LOH, however, was much lower, possibly reflecting the chromo-
some instability seen in higher ploidy cells.
Chromosome 11 showed involvement in CNAloss in 19 tumors
of which seven involved the whole chromosome (4 with LOH and
3 without). Of the 12 with subregional CNAloss, 10 were
accompanied by LOH, but 6 (50%) of these did not involve the
11p15-p13 region. Of the six tumors showing 11p deletions, five
did not extend to the 11p15 region containing the IGF2/H19
genes (the WT2 locus). An additional 18 tumors showed CNN
LOH, where 5 showed involvement of the whole chromosome and
5 were confined to 11p regions that did not contain the WT1 locus
(figure 4). Of the remaining seven LOH events, six spanned the
WT1/WT2 loci and only one showed LOH that excluded the
WT2 locus. Of the 12 tumors showing sub regional LOH, none
involved the long arm, in contrast with the tumors with CNAloss,
where 50% involved the long arm. Since WCL was seen in seven
cases, involvement of 11q occurred in 15 tumors (,28%). A
compound deletion was seen in GOS 96 resulting in a
homozygous deletion of the WT1 locus (figure 4). Of the tumors
showing LOH that extended to 11qter, the minimal region of
overlap (MRO) was defined as Chr11;102077451–125002355, by
tumors GOS 128, (Chr11:102077451-qter) and GOS 370 (Chr11;
66706205–125002355). The other interstitial deletion seen in
GOS370, which did not extend to qter, reduced the MRO to
Chr11:102077451–125002355. Overall, therefore, 37 tumors
(,66%) showed loss or LOH involving chromosome 11.
Gain of the long arm of chromosome 1 has been associated with
poor outcome [40]. In this series, 22 tumors (,40%) showed a
gain of 1q which, with the exception of GOS 26, involved the
entire long arm. Loss of a whole copy of chromosome 1 was never
seen, and only one tumor (GOS 548), showed LOH of Chr:1 on a
CNN background. Chromosome 1 showed loss of the short arm in
seven tumors, of which four were accompanied by a gain of the
long arm. 5/7 CNAloss events were accompanied by LOH and, in
all but GOS 11, involved loss of the entire chromosome arm.
The short arm of chromosome 3 showed losses in six tumors, of
which three represented CNN LOH (figure 5) and two involved
WCL. The common region of loss involved Chr3:40029744–
53237440.
Chromosome 16 has also been implicated in frequent LOH
[31,41–42], which has been related to clinical outcome [43–45].
One tumor in this series (GOS 404) showed whole chromosome 16
loss accompanied by LOH and six other tumors showed
subregional deletions involving only the long arm, of which only
2 showed coincident LOH. The breakpoints giving rise to the
deletions clustered in two distinct regions, one at ,31 Mbp and
the other at ,45 Mbp, both extending to 16qter. Interestingly,
only the deletions showing the 45 Mbp-qter loss showed LOH,
although both breakpoints occurred within the large heterochro-
matic regions on either side of the centromere of this chromosome.
Two other tumors (GOS 54 and GOS 439) showed CNN LOH
for non-overlapping regions of Chr16. Gains involving any part of
Chr16 were not observed.
Losses on chromosome 7p (figure 5) have also been described in
WT [46] and were observed in six tumors in this cohort. Of the 4
tumors showing subregional deletions, three were accompanied by
LOH, although neither of the two cases of WCL showed LOH.
The minimal LOH region on 7p was defined by GOS 120 as
Chr7:pter-46805718. In one case (GOS 44), as we reported
previously [47] using focused analysis of polymorphic loci, a
homozygous deletion was seen spanning the Chr7:14474403–
18712248 interval. Loss of 7p was only seen in the stage III/IV
tumors. Gains of whole chromosome 7 were seen in four tumors
but no examples of CNN LOH for Chr7 were observed. From the
three tumors showing subregional gains, the minimal region
involved Chr7:69218189-qter.
Loss of 9q has been reported to be related to increased
tumorigenicity [35]. In the current series, five tumors showed
losses involving chromosome 9. In three of these cases, the whole
chromosome was lost, of which one was associated with LOH and
one represented CNN LOH. In three other tumors, subregional
losses on the long arm were observed, two as CNN LOH, where
the minimal region of loss was defined by tumor GOS 439, as
Chr9;84192301–93960316 (figure 5), which overlaps with the
Chr9:85684008–112037919 region defined by Ruteshouser et al
[48]. This ,10 Mbp minimal region is a relatively gene dense
region carrying genes for protein kinase such as TRKB and SYK,
cell cycle related proteins GAS1 and CDK20, and the RASEF
member of the RAS family of proteins.
Losses involving chromosome 14 were seen in ten tumors. Six of
these involved the whole chromosome, of which 50% showed
LOH. Subregional deletions were seen in the other 4 with
Figure 1. aCGH analysis of copy number neutral LOH events in WT. Upper panels in each case show copy number status for each of the
identified tumors (GOS 16, 439, 219) on a Log2 scale (0=no change). The lower panel for each chromosome shows LOH status (see Materials and
Methods) coinciding with significant reduction in AB genotypes compared to homozygous AA and BB genotypes. These LOH regions are highlighted
by the horizontal bar in the copy number profile. In A-C all LOH events are accompanied by CNN aCGH profiles.
doi:10.1371/journal.pone.0018941.g001
CGH of Wilms Tumor
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defined by tumors GOS 407 and GOS 358 (figure 5).
Three tumors showed CNN LOH for chromosome 6, where the
common region of overlap, defined by tumors GOS 16 (figure 1)
and GOS 576, was Chr6:24916262–26252770. This region
contains a histone gene cluster and a solute carrier 17 (SLC17)
gene cluster. A non-overlapping deletion on 6q, which involved
LOH, was seen in GOS 100.
In a recent report by Yuan et al [35], a novel region of LOH
on chromosome 4q was defined in 8% of tumors. In our series,
ten tumors showed losses involving chromosome 4 (figure 1).
Half of these deletions involved the whole chromosome, of which
three were accompanied by LOH. Of the 5 tumors showing sub
regional 4q losses, four cases involved CNAloss of which
two showed LOH and one showed CNN LOH. The minimal
region of overlap for these deletions/LOH (excluding the non-
overlapping 4p deletion in GOS 404) involved the
Chr4:92539047–129243723 interval which includes the 2.4
Mbp region described by Yuan et al [35]. This region does
not encompass the FBXW7 gene at Chr4:153242411–
153456185, which was shown recently to be mutated in a small
(,4%) number of WT [49].
Figure 2. Copy number profiles for abnormalities on chromosome 11. In (A) chromosome 11 from tumor GOS 100 shows a gain of the short
arm, which is accompanied by LOH for the distal half of the chromosome arm. LOH is also seen (relative to the AA and BB genotypes) for the long arm
which shows a small interstitial region of amplification. In (B) interstitial loss on 11q coincides with LOH.
doi:10.1371/journal.pone.0018941.g002
CGH of Wilms Tumor
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which five involved the whole chromosome. The minimal region
of gain was Chr12:26989469–34451374 which includes a member
of the PI3K kinase family.
The TP53 gene is located on the short arm of chromosome
17 (Chr17:7577861–7590863). Mutations in this gene occur
infrequently and are more often seen in rare tumors with
anaplastic histology [50]. In the current series, CNAloss on
Chr17 was seen in six tumors, of which one involved whole
chromosome loss. The other five involved losses of 17p all of which
included the TP53 gene. The MRO was defined by GOS 404
(figure 6) which spanned Chr17:pter-10157411 and was the
only tumor accompanied by LOH. Interesting, in GOS 404, a
second region of CNAloss, also with LOH, was seen more
proximally on the short arm (figure 6). CNN LOH was also seen
in two other tumors (GOS 439, GOS 536) but involved the long
arm of the chromosome. The MRO for these 17q events was
Chr17:66017832–72094821.
Chromosome 19 (figure 6) was infrequently involved in CNAloss
although one tumor (GOS 21) showed a micro deletion spanning
Chr19:48104372–48373067, which was within a common deleted
region. Losses involving chromosome 21 occurred in 9 tumors (5
as WCL), where the maximum common region of overlap in the
other four was Chr21:22871547–31525365. Similarly, CNAloss of
chromosome 22 was observed in seven tumors of which two
involved subregional losses accompanied by LOH, where the
smallest region of loss was defined by GOS 206.
Chromosome 22q LOH has also been associated with poor
outcome [51]. In the current series we identified LOH involving
22q in 7 tumors of which 5 involved the whole chromosome.
Of the other two, the minimal deletion was defined as
Chr22:40456765-qter.
Analysis of aCGH profiles in tumors with different
histology
Within this series of tumors, histology subtype was only
available from 28/56 of the cases (50%). Overall there were 22
cases with reported favorable histology (FH) and 6 with
unfavorable histology (UH). Although these numbers are too
small to draw definite conclusions, there appears to be an excess of
three chromosome abnormalities that are associated with poor
survival in the unfavorable histology group. Thus, 4/6 (66%) of
UH cases showed gain of chromosome are 1q compared with 6/
22 (27%) in the confirmed FH group. Similarly, 3/6 UH (50%)
tumors showed losses of chromosome 16q compared with only 1/
22 (4.5%) of FH tumors. Finally, losses of chromosome 11 were
also seen in 50% of UH tumors compared with 7/22 (32%) in FH
tumors. All of the other molecular changes frequently seen in this
Figure 3. Summary of copy number losses and LOH in the Wilms tumor series. Distribution of copy number gains (red) and losses (blue)
throughout the genome of the Wilms tumor series (A). Distribution of LOH events throughout the WT genomes (B). Copy number neutral LOH events
are shown in red. LOH associated with copy number loss is shown in blue.
doi:10.1371/journal.pone.0018941.g003
CGH of Wilms Tumor
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appeared to be only associated with FH tumors. Clearly given the
small numbers of tumors for which histological sub-typing was
available, these observations only indicate trends but molecular
markers associated with poor outcome tumors are consistently
observed at higher frequency in UH tumors which is also a marker
for poor outcome.
Discussion
In this analysis of Wilms tumors, we have combined data from
LOH events on a CNN background with LOH associated with
CNAloss to provide a comprehensive analysis of genetic abnor-
malities at high resolution (,12 Kb) using SNP mapping arrays. In
many cases, comparison of overlapping CNA/LOH has high-
lighted subregions within chromosomes that are consistently lost,
potentially defining the location of tumor suppressor genes. Until
recently, LOH studies in WT had traditionally involved analyses
of microsatellite markers, although using this approach only low
resolution analysis was possible because of the small number of loci
studied. As such, integration of this data with higher resolution
studies is relatively imprecise. In addition, not all microsatellite loci
were informative in LOH analyses due to constitutional
homozygosity. In some cases, because of constitutional homozy-
gosity, the LOH status was not retrievable at critical loci, which
limited resolution and restricted the number of cases available for
correlative analyses. This technical shortcoming is largely
overcome by the SNP mapping arrays which do not require the
availability of constitutional DNA from the same patient [36] and,
because of the high density of polymorphic markers on the array,
the extent of LOH can be relatively accurately determined [37].
As a result of our analysis of WT, we have defined regions
throughout the genome that show consistent LOH. The two hit
hypothesis predicts exposure of recessive mutations in critical
Figure 4. Genetic changes involving the WT1 and WT2 loci. In (A) CNN LOH is identified on chromosome 11 in GOS 206 which is restricted to
the distal 11p15 region containing WT2. In contrast, in GOS 96 (B) the deletion is confined to the WT1 locus where one chromosome carries an
extensive deletion and the other homolog carries a micro deletion (indicated by the bar) spanning the WT1 locus.
doi:10.1371/journal.pone.0018941.g004
CGH of Wilms Tumor
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this series of WT, LOH events (generated by whatever means) was
seen in 45% of tumors.
LOH involving the short arm of chromosome 11 is a frequent
event in sporadic WT [21] and reflects the importance of the WT1
(11p13) and WT2 loci (11p15) in tumorigenesis. It has been
suggested that the WT1 locus in 11p13 is more frequently affected
in syndrome related tumors [35], especially where hereditary
deletions (in WAGR) or mutations (in DDS) are seen. Bilateral
tumors are also considered to be more likely to be the consequence
of genetic predisposition [15], which is supported by the fact that
75% of stage V tumors in this series showed LOH for 11p
extending to the WT1 and WT2 loci. In two cases, these LOH
events were present as the only abnormalities in the tumor,
suggesting an important role for this event in these tumors. Only
one other tumor (stage IV) showed LOH for 11p as the only
aCGH/LOH abnormality in this series, and only 2/13 stage I/II
tumors carried this abnormality.
Mutations in WT1, however, are infrequent in sporadic WT
[52] supporting an important role for the H19 and IGF2 imprinted
genes in 11p15, where LOH results in preferential loss of the
paternally silenced genes resulting in their over expression [35].
The IGF2 gene is located in Chr11:2150348–2162341, and H19 is
located ,200 kb distal to that. In our series, of the tumors showing
CNAloss involving 11p, only three (50%) showed exclusive loss of
the region harboring the IGF2 and three others showed loss
restricted to the WT1 locus. In contrast, of the 12 tumors showing
CNN LOH, eight involved both the IGF2 and WT1 loci, and the
other four showed exclusive loss of the IGF2 locus. Thus, there
appears to be two consequences of 11p loss. In tumors showing
CNAloss as a means of generating LOH, and hence only one copy
of the IFG2 locus, 50% show loss that does not involve IGF2 and
the other 50% involved both.
Despite the now well known involvement of loci on 11p in
Wilms tumorigenesis, deletions on the long arm of chromosome
are also common and have been associated with an increased risk
of relapse [53–54]. In the present series, 14% of the tumors
showed sub regional CNAloss involving 11q, but overall in 28% of
tumors, if whole chromosome losses are included. These
frequencies are consistent with the 19% reported by Wittmann
et al [53]. The high resolution capabilities of the 250 K SNP array
used in our studies defined Chr1:102077451–125002355 as the
MRO. In the study by Wittmann et al [53], although only 11
SNPs along the length of the chromosome arm were used, several
tumors showed LOH confined to the interval defined by markers
D11S2000 and D11S925. This region spans Chr11:105,659,004–
120,728,211, which is consistent with our analysis,.
Genome-wide scans for LOH also identified 16q as a relatively
frequent event in WT [31,41]. Although different studies used
different microsatellite markers, the overall conclusion was that the
whole arm of the chromosome was usually involved, which related
to the frequent observation of unbalanced chromosome translo-
cations involving chromosome 16 in WT [28–29,55–56]. Follow-
ing early evidence that LOH for 16q was related to poor outcome,
recent studies using large sample sizes confirmed that LOH on 16q
is related to early relapse and poorer survival [43–45], although no
Figure 5. Distinct genetic events in WT. In (A) a small deletion is
observed on chromosome 3p in GOS 536 which defines the MRO for
losses on this chromosome. In (B) loss of 7p and gain of 7q (iso-7q) in
GOS 21 reflects a common event in WT. The CNN LOH event in GOS 439
(C) involves a small region on 9q which defines the MRO for losses in
this series of WT. The overlapping deletions on chromosome 14 in GOS
358 (D) and GOS 407 (E) define the MRO of losses on this chromosome.
doi:10.1371/journal.pone.0018941.g005
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identified. In the present study, LOH for chromosome 16q, in any
form, was seen in 12 tumors, although only associated with LOH
in 50% of cases. Thus, the overall frequency of CNAloss/LOH
involving of 16q is ,16% which is comparable to the LOH
frequency of ,17% in large cohort analyses [40,43–44]. Also,
small numbers of markers spaced along the length of the
chromosome arm may overlook small regions of LOH. An
advantage of microsatellite analysis, however, is that LOH can be
identified if, as suggested by Grundy and colleagues [43–44], there
was ‘‘a definitely reduced intensity’’ of the minor allele. This
criterion allows LOH to be detected even if there is heterogeneity,
or presence of normal cells, in the tumor sample. In the SNP
mapping arrays, heterozygosity contributed by these complications
would tend not to report LOH, which might account for the
slightly lower frequency of 16q LOH in our series, although after
combining CNAloss and CNN LOH, there is no difference in
incidence between different studies. The high-resolution analysis
provided by the SNP mapping arrays, for this and other
chromosomes, offers the possibility of detecting critical sub regions
of 16q. In tumors with CNAloss, however, loss of 16q involved the
entire arm in 5/5 cases with all breakpoints located within the
heterochromatic regions flanking the centromere. The same was
true of breakpoints involving gain of 1q where, although different
Figure 6. Complex CNAs in WT. In (A) two regions of deletion on chromosome 17 are seen in GOS 404, in both cases accompanied by
amplification at adjacent regions. LOH is seen for the two deleted regions. In (B) deletion of the distal part of 19q is seen in GOS 404 which is
accompanied by LOH with a preceding region of gain on 19q.
doi:10.1371/journal.pone.0018941.g006
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heterochromatic regions on either side of the centromere on this
chromosome as well. What was striking on chromosome 16,
however, was the fact that CNN LOH in one tumor (GOS 439)
involved only a sub region of 16q, defining the MRO as
Chr16:45086927–53627194, albeit based on a single tumor. In
the study by Wittmann et al [40], there was also evidence from a
small numbers of tumors that suggested a region involving
,Chr16:54.4–55.5 Mbp, although only two microsatellite markers
were used in this region to assess LOH. Nonetheless, these
observations combined, suggest involvement of an ,10 Mbp
region which contains at least 40 annotated genes.
According to the two hit hypothesis [14], bilateral tumors are
more likely to be related to hereditary predisposition. In our series
there were only 6 confirmed stage V tumors and genetic instability
was very similar to that seen in the stage III/IV tumors. One of the
tumors in the series, GOS 358, was classified as hereditary since
the sister of this patient also developed WT. In this case there were
only minimal genetic changes with LOH only for chromosome 11
and regions on chromosome 14. This is consistent with the
observations by Ruteshouser et al [48] who demonstrated that
LOH frequency in tumors from patients that carried either
constitutive mutations in WT1, or acquired WT1 mutations in
their tumors, showed a decreased loss of heterozygosity (except for
the WT1 locus) using a genome microsatellite analysis compared
with tumors that were wild-type for WT1. In our series, several
tumors (GOS 566, GOS 178, GOS 543, GOS 586, GOS 504)
showed LOH involving the WT1/WT2 loci on chromosome 11 as
the only abnormality detected by the SNP arrays, although the
WT1 status in these tumors is not known and none were recorded
as hereditary. Several other tumors with LOH of 11p showed only
minimal, if any, additional CNA/LOH changes. These observa-
tions are consistent with the idea that loss of WT1/2 is a significant
driver event in Wilms tumorigenesis that does not require
significant additional changes, whereas tumors without 11p
abnormalities show more complex molecular karyotypes. The
presence of abnormalities involving only 11p was more prevalent
in the stage V tumors, which is consistent with this suggestion. In
one of these cases the 11p deletion was confined to the WT1 locus.
Several tumors apparently showed normal karyotypes which
was independent of stage and histology, since there were
representatives of this class in all but the stage V tumors (see
above), and at least one case from a tumor with unfavorable
histology. It appears, therefore, that molecular profiles are
becoming essential in the characterization of these tumors rather
than staging. For Wilms tumors, the staging system is based on
clinical parameters, and so the timing of diagnosis could provide a
lower or higher stage, which may not be related to the molecular
events that have occurred within the tumor cells.
In addition to the common LOH events seen in WT involving
1p, 7p, 11p, and 16q, several other regions of the genome have
been highlighted in individual studies. Although mutations in
specific genes have been described, their incidence is still relatively
low. The CTNNB1 (b-catenin) gene located on chromosome 3
(Chr3:41240942–41281939), for example shows mutations in
.10% of WT [56] and more often in tumors that carry WT1
mutations. In our study, we defined the Chr3:40029744–
53237440 interval as the MRO which encompasses CTNNB1,
suggesting this may be the driver for the rare LOH events on
chromosome 3.
In summary, we have undertaken a detailed analysis of a
relatively large cohort of WT using high resolution arrays that
define CNAs and LOH to define regions of consistent losses and
gains throughout the genome. As a result of this analysis, and
combined with other studies, a detailed genomic landscape has
been defined which provides a platform to identify genes related to
the development and progression of WT and which might serve as
unequivocal markers for poor outcome.
Materials and Methods
Tumor samples were collected immediately following surgical
resection during the period 1982–1992 and snap frozen in liquid
nitrogen. At the time of collection the diagnosis of WT was
confirmed, although in some cases the specific stage was not
recorded. Unfortunately, it has also not been possible to recover
this information retrospectively from some of the anonymized
legacy samples. Approval to use the DNA samples and a waiver of
consent was obtained from the Roswell Park Cancer Institute IRB
where the CGH analysis was performed. Verbal informed consent
for the use of these tumor samples was obtained from parents of
children involved, which was the accepted procedure at the
Hospital for Sick Children, London, UK, during the collection
period. DNA was prepared from the whole tumor sample from
snap frozen tissue using standard phenol/chloroform extraction
procedures.
Analysis of 250K Genotyping Arrays
For the analysis of individual tumors, allele signal summaries
and genotypes were generated from the .CEL files with the
command-line program apt-probeset-genotype (v. 1.6.0; the
Affymetrix Power Tool [APT] package). The files were processed
using the Bayesian Robust Linear Model with Mahalanobis
distance (BRLMM) algorithm implemented in APT [57] with a
quantile sketch normalization of 50,000 points and no background
correction. Array data from the International Hap Map project
was used in the normalization and as baseline reference signals for
copy number (CN) estimations. Copy number was estimated with
the apt-copynumber-pipeline program [58] with Gaussian
smoothing at 0.1 Mb. These basic functionalities are also available
in the CNAT4 software [59]. Copy number is estimated as a log-
sum of the normalized sample allele signals (S) against those of the
reference set (R): Log Ratio=log2 (Sa/(Ra+Rb)+Sb/(Ra+Rb))
where a and b refer to the alternative SNP alleles. A detailed
review of considerations for CNA analysis is described elsewhere
[37]. Losses and gains were called where .20 contiguous probes
showed variations in log2 ratios of +/2 0.3. The Gaussian
smoothed log2 were then viewed using aCGHViewer [60] which
separates each chromosome into an individual panel to explore in
greater detail.
LOH was estimated from the sample genotypes by a Hidden
Markov Model using the SNP-wise heterozygosity rate of the
reference population and a genotyping error of 0.02 (default) to
estimate the prior. The transition decay parameter (describing the
influence of the LOH state of neighboring SNPs) was set to 10 Mb.
The state prediction of "LOH" versus "retention of heterozygos-
ity" (1 or 0) by the HMM was used to map regions of empirical
LOH as described in detail elsewhere [37]. From our extensive
analysis of LOH parameters that represent true LOH in the
absence of a matched normal control, using our custom algorithm,
an LOH score of .50 can typically be used reliably to
demonstrate LOH. For LOH visualization we used two comple-
mentary approaches. Firstly, the LOH score for the loss of
heterozygosity is calculated by multiplying the reference homozy-
gous rate for a contiguous stretch of SNPs using an in-house script,
that has been classified as having likely LOH using the Hidden
Markov Model that is incorporated into CNAT 4.0.1. The
reference homozygosity rate is obtained from the allelic frequen-
CGH of Wilms Tumor
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HapMap project (data available at http://www.affymetrix.com).
The calculated p-value represents the likelihood that a contiguous
stretch of SNPs would be homozygous by chance alone, based on
the allelic frequencies defined by the control samples. The LOH
Score is then calculated using the -Log10(pLOHsample). The .CHP
files from the BRLMM analysis was also processed in Partek
Genomics Suite v6.4 where the A/B allele ratios were used to
generate ideograms for LOH as shown in figures 1–5. We used an
unpaired analysis where the probability of observing a heterozy-
gous SNP in a region of LOH is the genotype error rate. In a
region without LOH, the probability of observing a heterozygous
SNP is estimated using the observed frequency from the baseline
samples. The heterozygosity rate (HET rate) is calculated as the
number of AB calls/total number of calls, where low het rates
imply LOH. By default the frequency of heterozygous calls for a
normal region is 0.3. We used a het rate of ,0.07 for calling LOH
events. The allelic ratios for the SNPs at each reported event were
graphed and visually examined and any reported regions that were
found in areas of poor probe density or close to centromeres were
identified. The analysis limits the number of markers on the LOH
fragment to a minimum of 20. The LOH data was then
assimilated and compared with copy number data.
Supporting Information
Table S1 Summary of losses, gains and LOH in 56 WT
samples. Tumors are listed according to stage except where this
was not available (NA). Segmental (Seg) and whole chromosome
losses or gains (WCL, WCG) which were accompanied by LOH are
shown in bold. For some tumors histology was defined as either
favorable (FH) or unfavorable (UH) and deceased individuals are
defined as (*).
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